Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Not applicable Interventional

Ultra-hypofractionated Radiation in Prostate Cancer

NCT03486821
View directory record Official record
Conditions
Early Stage Prostate Cancer
Interventions
Hypofractionated Radiation
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

NCT00151047
View directory record Official record
Conditions
Prostate Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 21, 2026, 6:53 AM EDT
Completed No phase listed Observational

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

NCT00392938
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
antiandrogen therapy, docetaxel, C-11 acetate PET scan, F-18 FDG PET scan, Tc-99m bone scan, CT scan of the chest, abdomen and pelvis
Drug · Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 21, 2026, 6:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Value of Community Vital Signs in Primary Care

NCT02512835
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Cardiovascular Disease
Interventions
Community vital signs
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Early Staged Consent Before Prostate Biopsy

NCT03507725
View directory record Official record
Conditions
Prostate Cancer
Interventions
Meditation, Prostate Biopsy, Questionnaires
Behavioral · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004029
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant viral vaccine therapy, sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional

Minimally Invasive Surgical Therapy for BPH

NCT00064649
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
Device · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 21, 2026, 6:53 AM EDT
Not listed Phase 1 Interventional

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions
EP31670
Drug
Lead sponsor
Epigenetix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT06957691
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulation, Placebo
Drug
Lead sponsor
Shehzad Basaria, M.D.
Other
Eligibility
40 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

NCT02199197
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium Ra 223 Dichloride, Enzalutamide
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190
View directory record Official record
Conditions
Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Study in Benign Prostatic Hyperplasia

NCT01152190
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Garden City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

NCT00329797
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
Dietary Supplement · Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
80
States / cities
Chico, California • Los Angeles, California • Pomona, California + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02582749
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

NCT00942578
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Bevacizumab, Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 21, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

NCT05384535
View directory record Official record
Conditions
Prostate Cancer, Magnetic Resonance Imaging, Population at Risk
Interventions
Bi-parametric MRI
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 55 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities

NCT06838325
View directory record Official record
Conditions
Prostate Cancer Screening
Interventions
Prostate Cancer Screening
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

NCT00526591
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, conventional surgery
Drug · Procedure
Lead sponsor
Jorge A. Garcia, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 21, 2026, 6:53 AM EDT
Completed No phase listed Observational

Early Stage Prostate Cancer Cohort

NCT00011349
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Male only
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
13
States / cities
Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments

NCT04705038
View directory record Official record
Conditions
Prostate Cancer
Interventions
Patient Education
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Withdrawn Not applicable Interventional

Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors

NCT03459755
View directory record Official record
Conditions
Prostate Cancer
Interventions
Physical Activity
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 6:53 AM EDT